Plain-English translation of NCT06840704 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a special medical nutrition drink called Oral Impact® can reduce acute esophagitis—painful inflammation of the throat—that often develops during radiation therapy for lung cancer. About 121 people with lung cancer will be randomly assigned to either receive this nutrition drink or standard nutritional support during their radiation treatment. Researchers want to know if this medication can protect the throat and improve comfort during cancer care.
When people receive radiation therapy to treat lung cancer, the radiation can damage the esophagus (the tube that carries food to your stomach), causing pain, difficulty swallowing, and inflammation. There is a real need for safe ways to prevent or reduce this damage, and this treatment may help protect the esophagus during radiation.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the special nutrition drink or standard nutritional support. If you receive the medication, you will drink 250 ml (about 8 ounces) twice a day, starting on the day your radiation therapy begins and continuing for three weeks after treatment ends. You will continue your regular radiation therapy as planned, and the research team will monitor you for side effects and measure how much throat damage develops over time.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China